Imipenem resistance in Pseudomonas aeruginosa;Imipenem-resistenz bei Pseudomonas aeruginosa

Wiener Klinische Wochenschrift

Volumn 110, Issue 20, 1998, Pages 715-720

  Fille, Manfred ^a   Bauernfeind, Adolf ^b   Eberlein, Elke ^b   Jungwirth, Renate ^b   Schneider, Ines ^b   Speer, Gerhard ^c   Dierich, Manfred P ^a   Allerberger, Franz ^a,d  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY OF MUNICH   (Germany)

^c Anstaltsapotheke der U   (Austria)

^d Bundesstaatl B S U   (Austria)

Author keywords

Cross infection; Imipenem resistance; Meropenero resistance; P. aeruginosa

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM; CARBAPENEM; CEFAMANDOLE; CEFEPIME; CEFOXITIN; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; FOSFOMYCIN; FUSIDATE SODIUM; GENTAMICIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; NETILMICIN; OFLOXACIN; PENICILLIN G; PIPERACILLIN; PYOCIN; TAZOBACTAM; TEICOPLANIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CROSS INFECTION; GENERAL PRACTICE; HUMAN; INTENSIVE CARE; OUTPATIENT; PREVALENCE; PSEUDOMONAS AERUGINOSA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AUSTRIA; BACTERIAL TYPING TECHNIQUES; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; HUMANS; IMIPENEM; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 0032582579     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Vincent J-L, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin M-H, et al (1995) The prevalence of nosocomial infection in intensive care units in Europe. JAMA 274: 639-644
2. Acar JF (1985) Therapy for lower respiratory tract infections with imipenem/cilastatin: a review of worldwide experience. Rev Infect Dis 7 [Suppl] 3: 513-517
3. Bauernfeind A (1985) Imipenemaktivität gegenüber Pseudomonas aeruginosa. Fortschritte der antimikrobiellen und antineoplastischen Chemotherapie 4-5: 1077-1081
4. Quinn JP, Dude EJ, DiVencenzo CA, Lucks DA, Lerner SA (1986) Emergence of resistance to imipenem during therapy for Pseudomonas aerugionosa infection. J Infect Dis 154: 289-294
5. National Committee for Clinical Laboratory Standards (NCCLS) (1998) Performance standards for antimicrobial susceptibility testing. NCCLS document M100-S8, Vol 18. No.16
6. National Committee for Clinical Laboratory Standards (NCCLS) (1997) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS document M7-A4, Vol. 17, No. 2
7. Andrews JM, Baquero F, Beltran JM, Canton E, Crokaert F, Gobernado F, et al (1983) International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother 12: 357-361
8. Deutsches Institut für Normung: Medizinische Mikrobiologie und Immunologie (1992) Normen und weitere Unterlagen. DIN, Deutsches Institut für Normung e.V, 2. Aufl. Beuth, Berlin Köln
9. Fyfe JAM, Harris G, Govan JRW(1984) Revised pyocin typing method for Pseudomonas aeruginosa. J Clin Microbiol 20: 47-50
10. Ogle JW, Janda JM, Woods DE, Vasil ML (1987) Characterization and use of DNA probe as an epidemiological marker for Pseudomonas aeruginosa. J Infect Dis 155: 119-126
11. Grothues D., Tummler B (1987) Genome analysis of Pseudomonas aeruginosa by pulsed field inversion gel electrophoresis. FEMS Microbiol Lett 48: 419-422
12. Gaynes RP, Culver DH (1992) National nosocomial infection surveillance system. Resistance to imipenem among selected gram-negative bacilli in the United States. Infect Control Hosp Epidemiol 13: 10-14
13. Stratton CW, Ratner H, Johnton PE, Schaffner W (1992) Focused microbiologic surveillance by specific hospital unit as a sensitive means of defining antimicrobial resistance problems. Diag Microbiol Infect Dis 15: 3S-10S
14. Miro E, Navarro F, March F, Sanchez F, Mirelis B (1995) Emergence of different resistance mechanisms in Pseudomonas aeruginosa in a patient treated with imipenem. Eur J Clin Microbiol Infect Dis 14: 731-732
15. Shah P (1996) Resistenzsituation im klinischen Alltag. Arzneimitteltherapie 14: 319
16. Bauernfeind A (1996) Aktivität von Mcropenem, Imipenem und Ceftazidim bei Pseudomonas aeruginosa und Burkholderia cepacia von Patienten mit Mukoviszidose. Chemotherapie Journal 5 [Suppl] 9: 25-27
17. Satake S, Yoneyama H, Nakae T (1991) Role of OmpD2 and chromosomal β-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 28: 199-207
18. Fung-Tomc J, Kolek B, Bonner DP (1993) Ciprofloxacin-induced, low level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 37: 1289-1296
19. Neu H (1992) Resistance of Pseudomonas aeruginosa to imipenem. Infect Control Hosp Epidemiol 13: 7-9
20. Sumita Y, Fukasawa M (1996) Meropenem resistance in Pseudomonas aeruginosa. Chemotherapy 42: 47-56
21. Climo MW, Pastor A, Wong ES (1997) An outbreak of Pseudomonas aeruginosa related to contaminated urodynamic equipment. Infect Control Hosp Epidemiol 18: 509-510
22. Cobben NA, Drent M, Jonkers M, Wouters EF, Vaneechoutte M, Stobberingh EE (1996) Outbreak of severe Pseudomonas aeruginosa respiratory infections due to contaminated nebulizers. J Hosp Infect 33: 63-71
23. Doring G, Horz M, Ortelt J, Grupp H, Wolz C (1993) Molecular epidemiology of Pseudomonas aeruginosa in an intensive care unit. Epidemiol Infect 110: 427-436
24. Tomkins RG, Burke JF (1992) Infections of burn wounds. In: Bennett JV, Brachman PS (eds) Hospital infections. Little, Brown and Company, Boston Toronto London, pp 711-730
25. Ritter E, Bauernfeind A, Schemken-Birk EA, Urbanek C, Finger H (1995) Nosokomiale Kolonisation und Infektion von Intensivpatienten mit multiresistenten Pseudomonas aeruginosa-Stämmen. Zentralbl Hyg 197: 552-566